{"id":"W2133649749","doi":"10.1056/nejmoa035026","title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":915,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia","funders":"Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Enfuvirtide; Regimen; Medicine; Viral load; Internal medicine; Liter; Virology; Randomization; Drug resistance; Dolutegravir; Human immunodeficiency virus (HIV); Randomized controlled trial; Immunology; Gastroenterology; Antiretroviral therapy; Biology; Gp41; Microbiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006447487,0.0003143109,0.0005577549,0.0002000665,0.0004094648,0.0002894193,0.0003180896,0.0003460282,0.002922326],"category_scores_gemma":[0.0005775179,0.0002212353,0.0003696233,0.000264529,0.0004479252,0.0002735946,0.0002911371,0.0006175982,0.000188344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007277272,"about_ca_system_score_gemma":0.001646909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006738074,"about_ca_topic_score_gemma":0.02687872,"domain_scores_codex":[0.9997696,0.0001310342,0.00001362396,0.00002886856,0.00002132773,0.00003550429],"domain_scores_gemma":[0.9996318,0.00009643141,0.00006673948,0.00001321674,0.00002544022,0.0001665062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3360467,0.02450738,0.2398946,0.002850945,0.003005969,0.001307886,0.001711011,0.002129667,0.06061485,0.0008425976,0.009898124,0.3171903],"study_design_scores_gemma":[0.2495323,0.1162717,0.6070517,0.0004003943,0.002305723,0.001664618,0.001040827,0.00118689,0.003690637,0.0006685054,0.01611556,0.00007109867],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926895,0.004405051,0.0001921016,0.0006717529,0.00003438851,0.0005281237,0.0002245786,0.000009930988,0.001244399],"genre_scores_gemma":[0.9919049,0.004430994,0.0008218294,0.0009551202,0.00006666932,0.0007267446,0.0003193704,0.000005549727,0.0007688496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006738074,"threshold_uncertainty_score":0.01339769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01274361375654826,"score_gpt":0.2547374387986145,"score_spread":0.2419938250420663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}